Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease

Digestive Diseases and Sciences

Volumn 50, Issue 11, 2005, Pages 2009-2018

  Kahrilas, Peter J ^a,e   Miner, Philip ^b   Johanson, John ^c   Mao, Lian ^d   Jokubaitis, Leonard ^d   Sloan, Sheldon ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Oklahoma Foundation for Digestive Research   (United States)

^c Rockford Gastroenterology Associates   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e Section of Gastroenterology   (United States)

Author keywords

Gastroesophageal reflux disease symptoms; Nonerosive gastroesophageal reflux disease; Proton pump inhibitor; Rabeprazole

Indexed keywords

RABEPRAZOLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTACIDS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; OMEPRAZOLE;

EID: 27144502406     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-3000-3     Document Type: Article

References (33)

1. A Gallup Organization National Survey: Heartburn across America. Princeton, NJ, Gallup Organization, 1988
2. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448-1456, 1997
3. Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32:974-979, 1997
4. Jones T: Can we alter the cytokine balance in the management of infectious diseases? Braz J Infect Dis 1:149-150, 1997
5. Galmiche JP, Barthelemy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11:765-773, 1997
6. Smout AJ: Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 22:81-85, 1997
7. Havelund T, Lind T, Wiklund I, et al.: Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 94:1782-1789, 1999
8. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104:252-258, 1998
9. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA: Functional esophageal disorders. Gut 45(Suppl 2):II31-II36, 1999
10. Masclee AA, de Best AC, de Graaf R, Cluysenaer OJ, Jansen JB: Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 25:225-230, 1990
11. Mattioli S, Pilotti V, Spangaro M, et al.: Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci 34:71-78, 1989
12. Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L: Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 34:1890-1893, 1989
13. Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO: The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 83:358-361, 1988
14. Breumelhof R, Smout AJ: The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 86:160-164, 1991
15. Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ: The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 107:1741-1745, 1994
16. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079-1089, 1998
17. Cloud ML, Enas N, Humphries TJ, Bassion S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43:993-1000, 1998
18. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastrooesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49-57, 1999
19. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 45:845-853, 2000
20. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 97:1332-1339, 2002
21. Johanson J, Miner P, Jokubaitis L, Mao L, Sloan S: Rabeprazole significantly improves heartburn vs placebo in endoscopically negative GERD patients with moderate to severe symptoms [abstract]. Am J Gastroenterol 96(Suppl):S18, 2001
22. Bate CM, Griffin SM, Keeling PW, et al.: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 10:547-555, 1996
23. Storr M, Meining A, Allescher HD: Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 18:93-102, 2000
24. Soll AH, Fass R: Gastroesophageal reflux: practical management of a common, challenging disorder. Clin Cornerstone 1:1-17, 1999
25. Lambert R: Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:651-662, 1997
26. Freston JW, Malagelada JR, Petersen H, McCloy RF: Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 7:577-586, 1995
27. Sanders SW: Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2-34, 31, 1996
28. Bruley des Varannes S, Galmiche JP: Evaluation of Esophageal Sensitivity, vol. 22. Basel, Karger, 1994
29. Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom [abstract # G4613]. Gastroenterology 116:1999
30. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastrooesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37:7-12, 1995
31. Meyer JH, Lembo A, Elashoff JD, Fass R, Mayer EA: Duodenal fat intensifies the perception of heartburn. Gut 49:624-628, 2001
32. Carlsson R, Dent J, Watts R, et al.: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119-124, 1998
33. Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 18:875-882, 2003